SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Pictured: AstraZeneca's manufacturing facility in Sweden
Pipeline
AstraZeneca Abandons Neuroscience, Prioritizes Weight Loss, Immunology
Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro altogether.
April 29, 2025
 · 
3 min read
 · 
Tristan Manalac
Trendy halftone collage with business concept. Career success concept, business goal,achieve goal, progress in career, make efforts to grow professionally. Teamwork. Hand finish ladder, helping to climb higher. Template for web banner, social media banner. Vector illustration
Vaccines
HHS Unfreezes Vaxart’s COVID-19 Study, Resumes Funding as Headwinds Batter Vaccines Space
While Vaxart can proceed with its study, fellow COVID-19 vaccine developers GeoVax and Novavax continue to be hamstrung by various regulatory roadblocks.
April 29, 2025
 · 
2 min read
 · 
Tristan Manalac
Modern collage with halftone hands give and take money. Financial transaction. Money investments. Cash payment. Pay for something
Mergers & acquisitions
Biohaven Grabs a Foothold With $600M Windfall From Oberland Capital
Biohaven will use the money to bankroll commercial preparations for the spinocerebellar ataxia drug candidate troriluzole, which is currently under FDA review with a decision expected in the third quarter.
April 29, 2025
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage of hand holding an arrow showing fall. Modern design. Copy space.
Earnings
Regeneron Shares Tumble as Eylea Declines Make for a ‘Messy Quarter’ To Come
The company’s $3 billion in earnings for the first quarter missed on both top and bottom line, according to BMO Capital Markets. Adding insult to injury, the FDA declined to approve a prefilled syringe of its ophthalmology cornerstone.
April 29, 2025
 · 
1 min read
 · 
Annalee Armstrong
A human hand showing dollar golden coins in the jar with a colored background. Collage Art of finance
Earnings
Pfizer Announces Another $1.7B in Cost Savings, Including R&D Revamp
Pfizer’s R&D organization has been in flux for almost two years now, since the $43 billion acquisition of ADC specialist Seagen. The new cuts were revealed in the company’s Q1 earnings report.
April 29, 2025
 · 
2 min read
 · 
Annalee Armstrong
Water tap dripping dollar bills on gray background. Business and financial success concept. 3D Rendering
Manufacturing
With Pharma Throwing Billions At US Manufacturing, Where Is The Cash Going?
Major pharmaceutical companies are committing billions to US manufacturing in an effort to avoid steep tariffs threatened by President Donald Trump.
April 29, 2025
 · 
2 min read
 · 
Annalee Armstrong
FDA
FDA Alumni, Experts Call on Makary To Stand Up Against Agency’s Politicization
In a recent interview, FDA Commissioner Marty Makary said there “should be nothing political about the FDA.” Recent actions taken by HHS Secretary Robert F. Kennedy, Jr. and others within the department appear to be at odds with this sentiment.
April 29, 2025
 · 
6 min read
 · 
Heather McKenzie
Employees Walking In And Out Of The Door, Some Were Leaving Their Job And Some Were Being Hired At The Same Time. Full Length, Isolated On Solid Color Background. Vector, Illustration, Flat Design, Character.
Layoffs
Spruce Axes 55% of Staff, Leaving Shoestring Crew To Focus on New Rare Disease Asset
Spruce Biosciences is cutting over half of its employees as it looks to secure accelerated approval of a Sanfilippo syndrome therapy it recently acquired from BioMarin.
April 28, 2025
 · 
1 min read
 · 
Angela Gabriel
A monoclonal antibody (mAb or moAb) is an antibody made by cloning a unique white blood cell. All subsequent antibodies derived this way trace back to a unique parent cell. Coronavirus. 3d render
Bladder cancer
Pfizer’s Subcutaneous PD-1 Cuts Risks in Bladder Cancer but Misses Survival Endpoint
Pfizer’s sasanlimab, when used with standard of care, reduced the likelihood of disease recurrence or progression, death due to any cause or persistence of cancer cells by 32% in patients with high-risk non-muscle invasive bladder cancer.
April 28, 2025
 · 
1 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS